Core Viewpoint - Changshan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 148.82%, despite recent fluctuations in trading volume and net capital flow [1][2]. Group 1: Stock Performance - As of October 20, Changshan Pharmaceutical's stock price reached 49.74 CNY per share, with a market capitalization of 457.14 billion CNY [1]. - The stock has experienced a 2.05% increase during the trading session on October 20, with a trading volume of 3.56 billion CNY and a turnover rate of 0.80% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on June 19, where it recorded a net buy of -178 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 4.92 billion CNY, a year-on-year decrease of 13.42%, while the net profit attributable to shareholders was -29.09 million CNY, an increase of 37.98% year-on-year [2]. - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1]. Group 3: Shareholder Information - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per shareholder, an increase of 2.08% [2]. - The company has distributed a total of 1.81 billion CNY in dividends since its A-share listing, with 4.60 million CNY distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 10.55 million shares, an increase of 8.04 million shares from the previous period [3].

Core Viewpoint - Changshan Pharmaceutical experienced a 5.07% increase in stock price, reaching 50.99 CNY per share, with a trading volume of 976 million CNY and a market capitalization of 46.863 billion CNY as of October 15 [1] Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is located in the Hebei Free Trade Zone and was established on September 28, 2000, with its listing date on August 19, 2011 [1] - The company's main business involves the research, production, and sales of heparin series products, with revenue composition as follows: 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Fund Holdings - According to data, one fund under Bosera Asset Management holds a significant position in Changshan Pharmaceutical. The Bosera National Index 2000 ETF (159505) held 1,400 shares in the second quarter, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF (159505) was established on November 23, 2023, with a latest scale of 11.7815 million CNY. Year-to-date returns are 37.61%, ranking 997 out of 4,220 in its category, while the one-year return is 49.48%, ranking 579 out of 3,857 [2] Fund Manager Information - The fund manager of Bosera National Index 2000 ETF (159505) is Tang Yibing, who has been in the position for 3 years and 87 days. The total asset size of the fund is 9.874 billion CNY, with the best return during his tenure being 72.49% and the worst being -41.93% [3]

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical has shown significant trading activity and financial metrics, indicating a high level of investor interest and potential volatility in its stock performance [1][2]. - On September 11, Changshan Pharmaceutical's stock rose by 3.42%, with a trading volume of 1.446 billion yuan. The net financing purchase on that day was 14.843 million yuan, with a total financing and securities balance of 2.027 billion yuan, which is 4.50% of its market capitalization [1]. - The company has a high financing balance, exceeding the 90th percentile of the past year, indicating strong investor engagement. The securities lending balance is also at a high level, with a remaining quantity of 100 shares and a balance of 4,898 yuan [1]. Group 2 - As of September 10, the number of shareholders for Changshan Pharmaceutical was 48,100, a decrease of 2.90% from the previous period. The average circulating shares per person increased by 2.99% to 19,079 shares [2]. - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%. However, the net profit attributable to the parent company was -29.089 million yuan, showing a year-on-year increase of 37.98% [2]. - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed over the past three years. As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, increasing its holdings by 8.0391 million shares [3].

Group 1 - The stock of Changshan Pharmaceutical increased by 5.36% on September 11, reaching a price of 49.90 yuan per share, with a trading volume of 1.027 billion yuan and a turnover rate of 2.35%, resulting in a total market capitalization of 45.861 billion yuan [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products. The main business revenue composition is as follows: 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Yinhua Fund holds a significant position in Changshan Pharmaceutical. The Yinhua ChiNext 200 ETF (159575) held 4,000 shares in the second quarter, accounting for 2.02% of the fund's net value, making it the largest heavy stock [2] - The Yinhua ChiNext 200 ETF (159575) was established on December 20, 2023, with a latest scale of 9.2491 million. Year-to-date returns are 23.03%, ranking 1853 out of 4222 in its category, while the one-year return is 79.57%, ranking 763 out of 3798 [2] - The fund managers of Yinhua ChiNext 200 ETF are Zhang Yichi and Tan Yuefeng, with Zhang having a tenure of 4 years and 111 days and a total asset scale of 7.781 billion yuan, achieving a best return of 53.61% during his tenure [2]

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical has seen a significant increase in its stock price, with a rise of 5.36% to 49.90 CNY per share, and a total market capitalization of 45.861 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with its main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Bosera Fund has a significant position in Changshan Pharmaceutical, with the Bosera National Index 2000 ETF holding 1,400 shares, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF, established on November 23, 2023, has a latest scale of 11.7815 million CNY and has achieved a year-to-date return of 35.55%, ranking 834 out of 4,222 in its category [2] - The fund manager, Tang Yibing, has a tenure of 3 years and 53 days, with the fund's total asset scale at 9.874 billion CNY, achieving a best return of 86.4% and a worst return of -41.93% during his tenure [2]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On September 2, Changshan Pharmaceutical's stock fell by 4.27%, with a trading volume of 1.565 billion yuan. The net financing purchase on that day was 15.3582 million yuan, with a total financing and securities balance of 1.985 billion yuan [1] - The financing balance of Changshan Pharmaceutical accounts for 4.44% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of August 29, the number of shareholders of Changshan Pharmaceutical decreased to 49,500, while the average circulating shares per person increased by 6.61% to 18,525 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported an operating income of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.089 million yuan, which represents a year-on-year increase of 37.98% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [2]